~~<i id='4775B61277'><strike id='4775B61277'><tt id='4775B61277'><pre id='4775B61277'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

hotspot

author：entertainment 2025-09-28 02:28:31 - browse：2843

Venture capitalist Alexis Borisy Vanessa Leroy for STAT

EQRx is done, sold for its cash.

The once-buzzy but now dormant biotech company is being acquired by Revolution Medicines, a developer of cancer drugs, the companies announced Tuesday.

The all-stock deal is essentially a balance-sheet transfer of $1 billion in cash from EQRx to Revolution. What was left of EQRx’s drug pipeline is being shelved.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Affirmative action in medical school literally saved lives
Next article： STAT Virtual Event: How to Increase Diversity in Clinical Trials

hotspot

focus

explore

hotspot

knowledge

DanielHulshizer/APEightmonthsintohistenure,Johnson&Johnson’sR&Dchiefisputtingabigemphasisonm

WSS

Data show record exodus of life scientists from academia

Paxlovid should be available without a positive Covid test

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Kaiser Permanente unions announce official strike date

Is mRNA technology the right fit for flu shots? Experts aren’t so sure

Cigna to pay $172 million to settle Medicare Advantage fraud probe

knowledge

hotspot

hotspot

What does generative AI mean for health care? We asked experts

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

23andMe had bad news about my health. I wish a person had delivered it

FDA seeks to regulate lab

Duchenne breakthrough therapy leaves behind pioneering families

Diagnostic tests are hitting their mathematical limits

Activists slam private health insurers over coverage restrictions

Why do women spend more than men on medical expenses?

How to save PrEP access — and even expand it

Address the ethical violations that led to 'Three Identical Strangers'

focus

Saudi VC loops Novo Nordisk, biotech VCs into longevity incubator

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Did you have Obamacare on your GOP debate bingo card?

Readout Newsletter: The latest in Pfizer, Moderna, and Sanofi

Paxlovid should be available without a positive Covid test

Rep. Raul Ruiz on the physician shortage and more

focus

explore

hotspot

knowledge